US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace

CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.

The Office of Compliance in the US Food and Drug Administration’s drug center has warning letter numbers and other statistics about the agency’s regulation of the dietary supplement industry. Findings of supplements marketed with drug claims and containing undisclosed drugs have increased during the COVID-19 pandemic, says the office’s director, Donald Ashley.

Ashley also offers a cautionary note to temper expectations for the FDA’s enforcement in the sector.